A randomized, double-blind, parallel group, 52-week study evaluating the efficacy, safety and tolerability of NVA237 in patients with poorly controlled asthma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
The study will assess efficacy, safety and tolerability of NVA237 compared to placebo in patients with poorly controlled asthma over 52 weeks of treatment.
Epistemonikos ID: 997d459ff0e50e8865763950e613ce6428c02fe5
First added on: May 11, 2024